{
    "Trade/Device Name(s)": [
        "Audit\u2122M MicroCV\u2122 Tumor Markers Linearity Set"
    ],
    "Submitter Information": "Aalto Scientific, Ltd.",
    "510(k) Number": "K082717",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042318"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "September 16, 2008",
    "Summary Letter Received Date": "September 18, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality Control Material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Alpha fetoprotein (AFP)",
        "Carcinoembryonic antigen (CEA)",
        "CA 125",
        "CA 15-3",
        "Prostate specific antigen-free (free PSA)",
        "Total PSA"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Quality control material",
        "Proficiency testing material"
    ],
    "Document Summary": "FDA 510(k) summary for Audit\u2122M MicroCV\u2122 Tumor Markers Linearity Set as a five-level human serum-based QC material for tumor marker assay calibration and proficiency testing.",
    "Indications for Use Summary": "Simulates human serum for verifying and validating the analytical measurement range of non-waived tumor marker testing methods; may be used for proficiency testing in interlaboratory surveys.",
    "fda_folder": "Clinical Chemistry"
}